5-HT<sub>1D</sub> receptor | 5-Hydroxytryptamine receptors | IUPHAR/BPS Guide to PHARMACOLOGY

5-HT1D receptor

Target id: 3

Nomenclature: 5-HT1D receptor

Family: 5-Hydroxytryptamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for 5-HT1D receptor in GtoImmuPdb

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 377 1p36.3-p34.3 HTR1D 5-hydroxytryptamine receptor 1D 47
Mouse 7 374 4 D3 Htr1d 5-hydroxytryptamine (serotonin) receptor 1D 48
Rat 7 374 5q36 Htr1d 5-hydroxytryptamine receptor 1D 10
Previous and Unofficial Names
5-HT1Dα [47] | HTRL | 5-HT1D | HT1DA | serotonin receptor 1D | Gpcr14 | Htr1db | 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled
Database Links
Specialist databases
GPCRDB 5ht1d_human (Hs), 5ht1d_mouse (Mm), 5ht1d_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
5-hydroxytryptamine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]eletriptan Hs Full agonist 9.1 pKd 28
pKd 9.1 (Kd 9x10-10 M) [28]
[3H]5-CT Hs Agonist 9.1 pKd 51
pKd 9.1 (Kd 9x10-10 M) [51]
[3H]8-OH-DPAT Hs Full agonist 9.0 pKd 29
pKd 9.0 (Kd 1x10-9 M) [29]
[125I]GTI Rn Agonist 8.9 pKd 2-3
pKd 8.9 (Kd 1.3x10-9 M) [2-3]
[3H]alniditan Hs Full agonist 8.9 – 8.9 pKd 18
pKd 8.9 – 8.9 (Kd 1.4x10-9 – 1.2x10-9 M) [18]
[3H]5-HT Hs Full agonist 8.2 – 8.6 pKd 18,41,47
pKd 8.2 – 8.6 [18,41,47]
[3H]sumatriptan Hs Full agonist 8.2 pKd 28
pKd 8.2 (Kd 7x10-9 M) [28]
donitriptan Rn Full agonist 9.6 pKi 14
pKi 9.6 [14]
dihydroergotamine Hs Full agonist 9.2 – 9.9 pKi 11,18-19
pKi 9.2 – 9.9 [11,18-19]
oxymetazoline Hs Partial agonist 9.4 pKi 17
pKi 9.4 [17]
donitriptan Hs Full agonist 9.3 pKi 14
pKi 9.3 [14]
7-methoxy-1-naphthylpiperazine Hs Full agonist 9.2 pKi 15
pKi 9.2 [15]
lysergol Hs Full agonist 9.2 pKi 47
pKi 9.2 [47]
ergotamine Hs Agonist 9.1 pKi 9
pKi 9.1 (Ki 8x10-10 M) [9]
PNU109291 Gg Agonist 9.1 pKi 7
pKi 9.1 (Ki 9x10-10 M) [7]
alniditan Hs Full agonist 8.7 – 9.4 pKi 18-19
pKi 8.7 – 9.4 [18-19]
L-694,247 Hs Agonist 9.0 pKi 50
pKi 9.0 (Ki 1x10-9 M) [50]
lisuride Hs Partial agonist 9.0 pKi 23
pKi 9.0 [23]
ziprasidone Hs Full agonist 9.0 pKi 40
pKi 9.0 [40]
5-CT Hs Full agonist 8.6 – 9.2 pKi 11,19,47
pKi 8.6 – 9.2 [11,19,47]
eletriptan Hs Full agonist 8.9 pKi 28
pKi 8.9 (Ki 1.26x10-9 M) [28]
zolmitriptan Hs Full agonist 8.9 pKi 28
pKi 8.9 [28]
lysergic acid Hs Full agonist 8.8 – 9.0 pKi 19
pKi 8.8 – 9.0 [19]
GR 127935 Hs Partial agonist 8.6 – 9.1 pKi 8,15,35,41,46
pKi 8.6 – 9.1 [8,15,35,41,46]
naratriptan Hs Full agonist 8.4 – 9.0 pKi 6,28,37
pKi 8.4 – 9.0 [6,28,37]
CGS-12066 Hs Full agonist 8.5 – 8.6 pKi 11,47
pKi 8.5 – 8.6 [11,47]
5-hydroxytryptamine Hs Full agonist 8.0 – 9.0 pKi 4,11,19,29,41,46-47
pKi 8.0 – 9.0 [4,11,19,29,41,46-47]
asenapine Hs Full agonist 8.4 pKi 40
pKi 8.4 [40]
frovatriptan Hs Agonist 8.4 pKi 52
pKi 8.4 (Ki 4.4x10-9 M) [52]
sumatriptan Hs Full agonist 8.0 – 8.7 pKi 11,19,24,28,47
pKi 8.0 – 8.7 (Ki 1x10-8 – 1.99x10-9 M) [11,19,24,28,47]
xanomeline Hs Full agonist 8.2 pKi 44
pKi 8.2 [44]
1-naphthylpiperazine Hs Full agonist 8.1 – 8.2 pKi 15,47
pKi 8.1 – 8.2 [15,47]
cabergoline Hs Partial agonist 8.1 pKi 23
pKi 8.1 [23]
5-MeOT Hs Full agonist 7.4 – 8.7 pKi 11,19,47
pKi 7.4 – 8.7 [11,19,47]
bromocriptine Hs Partial agonist 8.0 pKi 23
pKi 8.0 [23]
BRL-15572 Hs Partial agonist 7.9 pKi 35
pKi 7.9 [35]
pergolide Hs Partial agonist 7.9 pKi 23
pKi 7.9 [23]
rizatriptan Hs Full agonist 7.9 pKi 28
pKi 7.9 [28]
terguride Hs Partial agonist 7.8 pKi 23
pKi 7.8 [23]
RU 24969 Hs Full agonist 7.7 pKi 11
pKi 7.7 [11]
SB 216641 Hs Partial agonist 7.6 pKi 35
pKi 7.6 [35]
aripiprazole Hs Full agonist 7.2 pKi 42
pKi 7.2 [42]
dimethyltryptamine Hs Full agonist 7.0 – 7.3 pKi 19
pKi 7.0 – 7.3 [19]
TFMPP Hs Full agonist 7.1 – 7.2 pKi 11,47
pKi 7.1 – 7.2 [11,47]
8-OH-DPAT Hs Full agonist 6.9 – 7.3 pKi 6,19,28
pKi 6.9 – 7.3 [6,19,28]
tryptamine Hs Full agonist 6.8 – 7.4 pKi 19,47
pKi 6.8 – 7.4 [19,47]
roxindole Hs Partial agonist 7.0 – 7.2 pKi 23,29
pKi 7.0 – 7.2 [23,29]
EMDT Hs Full agonist 6.5 pKi 9
pKi 6.5 [9]
clozapine Hs Full agonist 6.4 pKi 40
pKi 6.4 [40]
α-methyl-5-HT Hs Full agonist 6.1 – 6.6 pKi 19
pKi 6.1 – 6.6 [19]
LY344864 Hs Full agonist 6.2 pKi 31
pKi 6.2 [31]
olanzapine Hs Full agonist 6.2 pKi 40
pKi 6.2 [40]
2-methyl-5-HT Hs Full agonist 5.7 – 6.2 pKi 19,47
pKi 5.7 – 6.2 [19,47]
quetiapine Hs Full agonist 5.7 pKi 40
pKi 5.7 [40]
capeserod Hs Partial agonist 5.1 pKi 26
pKi 5.1 [26]
dipropyl-5-CT Hs Full agonist 7.9 pIC50 47
pIC50 7.9 [47]
CP-122288 Hs Full agonist 7.7 pIC50 6
pIC50 7.7 [6]
View species-specific agonist tables
Agonist Comments
Frovatriptan is selective for 1B and 1D 5-HT receptor subtypes over the 1A subtype [52].
BRL-15572 can be used to distinguish between 5-HT1D and 5-HT1B receptors, being approximately 60-fold selective for the 1D subtype [35].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]GR 125,743 Hs Antagonist 8.6 pKd 51
pKd 8.6 (Kd 2.8x10-9 M) [51]
zotepine Hs Antagonist 9.3 pKi 40
pKi 9.3 [40]
SB 714786 Hs Antagonist 9.1 pKi 43
pKi 9.1 (Ki 7.94x10-10 M) [43]
metergoline Hs Antagonist 8.6 – 9.2 pKi 6,11,19
pKi 8.6 – 9.2 [6,11,19]
SB 649915 Hs Antagonist 8.8 pKi 43
pKi 8.8 [43]
ocaperidone Hs Antagonist 8.7 – 8.8 pKi 19
pKi 8.7 – 8.8 [19]
SB 272183 Hs Antagonist 8.7 pKi 45
pKi 8.7 [45]
methysergide Hs Antagonist 8.4 – 8.9 pKi 19,47
pKi 8.4 – 8.9 [19,47]
GR 127935 Hs Antagonist 8.3 – 8.6 pKi 19
pKi 8.3 – 8.6 [19]
9-OH-risperidone Hs Antagonist 7.9 pKi 40
pKi 7.9 [40]
risperidone Hs Antagonist 7.8 – 8.0 pKi 19,40
pKi 7.8 – 8.0 [19,40]
bufotenine Hs Antagonist 7.7 – 8.0 pKi 19
pKi 7.7 – 8.0 [19]
rauwolscine Hs Antagonist 7.8 pKi 47
pKi 7.8 [47]
methiothepin Hs Inverse agonist 7.3 – 8.2 pKi 6,11,19,46
pKi 7.3 – 8.2 [6,11,19,46]
ritanserin Hs Antagonist 7.6 pKi 19
pKi 7.6 [19]
(+)-WAY 100135 Hs Antagonist 7.6 pKi 4
pKi 7.6 [4]
ketanserin Hs Antagonist 7.4 – 7.5 pKi 6,19
pKi 7.4 – 7.5 [6,19]
yohimbine Hs Antagonist 7.2 – 7.7 pKi 11,19,24,47
pKi 7.2 – 7.7 [11,19,24,47]
sertindole Hs Antagonist 7.2 pKi 40
pKi 7.2 [40]
cyanopindolol Hs Antagonist 7.1 pKi 11
pKi 7.1 [11]
S33084 Hs Antagonist 6.9 pKi 22
pKi 6.9 [22]
pipamperone Hs Antagonist 6.8 pKi 40
pKi 6.8 [40]
m-chlorophenylpiperazine Hs Antagonist 6.7 pKi 11
pKi 6.7 [11]
haloperidol Hs Antagonist 6.6 pKi 40
pKi 6.6 [40]
SB 224289 Hs Antagonist 6.3 pKi 8,41
pKi 6.3 [8,41]
fluspirilene Hs Antagonist 6.0 pKi 40
pKi 6.0 [40]
SB 277011-A Hs Antagonist 5.8 pKi 36
pKi 5.8 [36]
spiperone Hs Antagonist 5.5 – 6.0 pKi 11,47
pKi 5.5 – 6.0 [11,47]
MPDT Hs Antagonist 5.2 pKi 9
pKi 5.2 [9]
L-772,405 Hs Antagonist 9.0 pIC50 39
pIC50 9.0 [39]
vortioxetine Rn Antagonist 5.4 pIC50 12
pIC50 5.4 (IC50 4x10-6 M) [12]
View species-specific antagonist tables
Allosteric Modulators
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
5-HT-moduline Hs Negative 12.0 pIC50 38
pIC50 12.0 [38]
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  11,20
Tissue Distribution
Trigeminal ganglion.
Species:  Human
Technique:  immunocytochemistry.
References:  13
Spinal cord: dorsal horn > ventral horn.
Species:  Human
Technique:  Radioligand binding.
References:  16
Poorly expressed in coronary arteries, atrium, ventricle and epicardium.
Species:  Human
Technique:  RT-PCR.
References:  30
Benign and malignant prostate tissue.
Species:  Human
Technique:  Western blotting.
References:  5
Globus pallidus > frontal cortex > putamen.
Species:  Human
Technique:  Radioligand binding.
References:  25
Trigeminal ganglion.
Species:  Rat
Technique:  Immunohistochemistry.
References:  21
Dorsal root ganglion and trigeminal ganglion.
Species:  Rat
Technique:  immunocytochemistry.
References:  34
Lumbar dorsal root ganglia, superior cervical ganglia, lumbar sympathetic ganglia.
Species:  Rat
Technique:  RT-PCR.
References:  32
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in mouse adrenal Y-1 cells transfected with the 5-HT1D receptor.
Species:  Human
Tissue:  Y-1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  47
Physiological Functions
Growth hormone release.
Species:  Human
Tissue:  In vivo.
References:  27,49
Inhibition of 5-HT release.
Species:  Rat
Tissue:  in vivo and mesencephalic raphe slices.
References:  33
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Htr1dtm1Lex Htr1dtm1Lex/Htr1dtm1Lex
involves: 129S5/SvEvBrd * C57BL/6J
MGI:96276  MP:0002169 no abnormal phenotype detected
Biologically Significant Variants
Type:  Single nucleotide polymorphisms
Species:  Human
Description:  Three polymorphisms, 1123 T -> G, 628 T-> C and 2190 A -> G have a possible association with anorexia nervosa.
References:  1

References

Show »

1. Bergen AW, van den Bree MB, Yeager M, Welch R, Ganjei JK, Haque K, Bacanu S, Berrettini WH, Grice DE, Goldman D, Bulik CM, Klump K, Fichter M, Halmi K, Kaplan A, Strober M, Treasure J, Woodside B, Kaye WH. (2003) Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol Psychiatry, 8: 397-406. [PMID:12740597]

2. Boulenguez P, Segu L, Chauveau J, Morel A, Lanoir J, Delaage M. (1992) Biochemical and pharmacological characterization of serotonin-O-carboxymethylglycyl[125I]iodotyrosinamide, a new radioiodinated probe for 5-HT1B and 5-HT1D binding sites. J. Neurochem., 58 (3): 951-9. [PMID:1738002]

3. Bruinvels AT, Palacios JM, Hoyer D. (1993) Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch. Pharmacol., 347 (6): 569-82. [PMID:8361548]

4. Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (1997) (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol, 121: 737-742. [PMID:9208142]

5. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate, 59: 328-336. [PMID:15042609]

6. Domenech T, Beleta J, Palacios JM. (1997) Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol, 356: 328-334. [PMID:9303569]

7. Ennis MD, Ghazal NB, Hoffman RL, Smith MW, Schlachter SK, Lawson CF, Im WB, Pregenzer JF, Svensson KA, Lewis RA et al.. (1998) Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects. J. Med. Chem., 41 (13): 2180-3. [PMID:9632349]

8. Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD. (1998) The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem, 41: 1218-1235. [PMID:9548813]

9. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK. (2000) 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem, 43: 1011-1018. [PMID:10715164]

10. Hamblin MW, McGuffin RW, Metcalf MA, Dorsa DM, Merchant KM. (1992) Distinct 5-HT1B and 5-HT1D serotonin receptors in rat: structural and pharmacological comparison of the two cloned receptors. Mol. Cell. Neurosci., 3: 578-587.

11. Hamblin MW, Metcalf MA. (1991) Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol, 40: 143-148. [PMID:1652050]

12. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem., 47 (19): 4684-92. [PMID:15341484]

13. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res, 909: 112-120. [PMID:11478927]

14. John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FC. (1999) F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther, 290: 83-95. [PMID:10381763]

15. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. (1997) 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem, 40: 3974-3978. [PMID:9397179]

16. Laporte AM, Doyen C, Nevo IT, Chauveau J, Hauw JJ, Hamon M. (1996) Autoradiographic mapping of serotonin 5-HT1A, 5-HT1D, 5-HT2A and 5-HT3 receptors in the aged human spinal cord. J Chem Neuroanat, 11: 67-75. [PMID:8841890]

17. Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersad V, Prisinzano T, Glennon RA. (1998) Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. J Med Chem, 41: 2243-2251. [PMID:9632357]

18. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE. (1998) Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol, 123: 1655-1665. [PMID:9605573]

19. Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R, Lesage AS. (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol, 50: 1567-1580. [PMID:8967979]

20. Lin SL, Setya S, Johnson-Farley NN, Cowen DS. (2002) Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol, 136: 1072-1078. [PMID:12145108]

21. Ma QP. (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport, 12: 1589-1591. [PMID:11409721]

22. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 293: 1048-1062. [PMID:10869410]

23. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303: 791-804. [PMID:12388666]

24. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A. (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse, 35: 79-95. [PMID:10611634]

25. Miller KJ, Teitler M. (1992) Quantitative autoradiography of 5-CT-sensitive (5-HT1D) and 5-CT-insensitive (5-HT1E) serotonin receptors in human brain. Neurosci Lett, 136: 223-226. [PMID:1641195]

26. Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrie P, Scatton B. (2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther, 302: 731-741. [PMID:12130738]

27. Mota A, Bento A, Penalva A, Pombo M, Dieguez C. (1995) Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion. J Clin Endocrinol Metab, 80: 1973-1977. [PMID:7775648]

28. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol, 368: 259-268. [PMID:10193663]

29. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol, 359: 447-453. [PMID:10431754]

30. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol, 372: 49-56. [PMID:10374714]

31. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD, Branchek TA, Flaugh ME. (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci, 61: 2117-212. [PMID:9395253]

32. Pierce PA, Xie GX, Levine JD, Peroutka SJ. (1996) 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience, 70: 553-559. [PMID:8848158]

33. Pineyro G, de Montigny C, Blier P. (1995) 5-HT1D receptors regulate 5-HT release in the rat raphe nuclei. In vivo voltammetry and in vitro superfusion studies. Neuropsychopharmacology, 13: 249-260. [PMID:8602897]

34. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci, 23: 10988-10997. [PMID:14645495]

35. Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Gothert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. (1997) SB-216641 and BRL-15572 compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch. Pharmacol., 356: 312-320. [PMID:9303567]

36. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther, 294: 1154-1165. [PMID:10945872]

37. Reynolds GP, Mason SL, Meldrum A, De Keczer S, Parnes H, Eglen RM, Wong EH. (1995) 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br J Pharmacol, 114: 993-998. [PMID:7780656]

38. Rousselle JC, Plantefol M, Fillion MP, Massot O, Pauwels PJ, Fillion G. (1998) Specific interaction of 5-HT-moduline with human 5-HT1b as well as 5-HT1d receptors expressed in transfected cultured cells. Naunyn Schmiedebergs Arch Pharmacol, 358: 279-286. [PMID:9774213]

39. Russell MG, Matassa VG, Pengilley RR, van Niel MB, Sohal B, Watt AP, Hitzel L, Beer MS, Stanton JA, Broughton HB, Castro JL. (1999) 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem, 42: 4981-5001. [PMID:10585208]

40. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 124: 57-73. [PMID:8935801]

41. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW. (1998) SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol, 125: 202-208. [PMID:9776361]

42. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28: 1400-1411. [PMID:12784105]

43. Ward SE, Harrington FP, Gordon LJ, Hopley SC, Scott CM, Watson JM. (2005) Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem, 48: 3478-3480. [PMID:15887956]

44. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM. (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol, 125: 1413-1420. [PMID:9884068]

45. Watson J, Roberts C, Scott C, Kendall I, Collin L, Day NC, Harries MH, Soffin E, Davies CH, Randall AD, Heightman T, Gaster L, Wyman P, Parker C, Price GW, Middlemiss DN. (2001) SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol, 133: 797-806. [PMID:11454652]

46. Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN. (1996) GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors. Eur J Pharmacol, 314: 365-372. [PMID:8957260]

47. Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc. Natl. Acad. Sci. U.S.A., 89: 3630-3634. [PMID:1565658]

48. Weydert A, Cloez-Tayarani I, Fillion MP, Simon-Chazottes D, Guenet JL, Fillion G. (1992) Molecular cloning of two partial serotonin 5-HT1D receptor sequences in mouse and one in guinea pig. C R Acad Sci III, 314: 429-435. [PMID:1521164]

49. Whale R, Bhagwagar Z, Cowen PJ. (1999) Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?. Psychopharmacology (Berl), 145: 223-226. [PMID:10463324]

50. Wurch T, Colpaert FC, Pauwels PJ. (1998) Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. Mol. Pharmacol., 54 (6): 1088-96. [PMID:9855638]

51. Xie Z, Lee SP, O'Dowd BF, George SR. (1999) Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett., 456 (1): 63-7. [PMID:10452531]

52. Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE. (1999) N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist. J. Med. Chem., 42 (3): 526-31. [PMID:9986723]

Contributors

Show »

How to cite this page

Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon, Paul R. Hartig, René Hen, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer, Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss, Ewan Mylecharane, Stephen J. Peroutka, Pramod R. Saxena, Andrew Sleight, Carlos M. Villalon, Frank Yocca.
5-Hydroxytryptamine receptors: 5-HT1D receptor. Last modified on 16/02/2018. Accessed on 17/11/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3.